{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T07:10:52Z","timestamp":1778483452303,"version":"3.51.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.critrevonc.2026.105286","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:18:34Z","timestamp":1774052314000},"page":"105286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["When immunity backfires: Meta-analysis on sarcoidosis reactivation in cancer patients treated with immune checkpoint inhibitors"],"prefix":"10.1016","volume":"222","author":[{"given":"Serafina","family":"Martella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Cusumano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Stylianakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Porcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Saba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nerina","family":"Denaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Buisseret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giusi","family":"Bond\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Vancheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Solinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.critrevonc.2026.105286_bib1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.21037\/atm-20-8124","article-title":"Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease","volume":"9","author":"Alexander","year":"2021","journal-title":"Ann. Transl. Med"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105286_bib2","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.cllc.2023.05.006","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Cancer Patients and Preexisting Autoimmune Disease: A Systematic Review and Meta-Analysis in Non-Small-Cell Lung Cancer","volume":"24","author":"Aung","year":"2023","journal-title":"Clin. Lung Cancer"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105286_bib3","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105286_bib4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejca.2021.05.041","article-title":"ICIR; Coordination; Co-Convenors; Steering Committee; Research Fellows; Data Scientist. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation","volume":"158","author":"Chanson","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105286_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e27612","article-title":"Advance in pathogenesis of sarcoidosis: Triggers and progression","volume":"10","author":"Chen","year":"2024","journal-title":"Heliyon"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105286_bib6","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jaad.2018.07.051","article-title":"Immune checkpoint inhibitors and the development of granulomatous reactions","volume":"81","author":"Cornejo","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.critrevonc.2026.105286_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105286_bib8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105286_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105286_bib10","first-page":"1404","article-title":"Soluble IL-2 receptor levels support diagnosis of sarcoidosis-like reaction in melanoma patients on immunotherapy - a diagnostic algorithm based on a single center retrospective study","volume":"23","author":"Gussek","year":"2025","journal-title":"J. Dtsch Dermatol. Ges."},{"key":"10.1016\/j.critrevonc.2026.105286_bib11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","author":"Gutzmer","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105286_bib12","first-page":"624","article-title":"Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data","volume":"31","author":"Guven","year":"2023","journal-title":"Support Care Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105286_bib13","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jamaoncol.2022.2081","article-title":"Association Between Toxic Effects and Survival in Patients With Cancer and Autoimmune Disease Treated With Checkpoint Inhibitor Immunotherapy","volume":"8","author":"Han","year":"2022","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105286_bib14","doi-asserted-by":"crossref","first-page":"21463","DOI":"10.3390\/ijms141121463","article-title":"Imbalance between Th17 and regulatory T-Cells in sarcoidosis","volume":"14","author":"Huang","year":"2013","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105286_bib15","first-page":"278","article-title":"Association Between PET\/CT Metabolic Parameters and Serum ACE and Calcium Levels in Sarcoidosis","volume":"16","author":"Incekara","year":"2026","journal-title":"Diagn. (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105286_bib16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.25082\/CCR.2023.01.004","article-title":"Risk of severe immune-related adverse events in cancer patients with pre-existing autoimmunity receiving immune checkpoint inhibitor therapy","volume":"5","author":"Isaacs","year":"2024","journal-title":"Curr. Cancer Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105286_bib17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105286_bib18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2217\/imt-2020-0272","article-title":"Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis","volume":"13","author":"Kim","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.critrevonc.2026.105286_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106161","article-title":"Current perspectives on the immunopathogenesis of sarcoidosis","volume":"173","author":"Lee","year":"2020","journal-title":"Respir. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105286_bib20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12885-024-12256-z","article-title":"Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105286_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114148","article-title":"A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease","volume":"207","author":"Lopez-Olivo","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105286_bib22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s41927-022-00297-5","article-title":"Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy","volume":"6","author":"Lusa","year":"2022","journal-title":"BMC Rheuma"},{"key":"10.1016\/j.critrevonc.2026.105286_bib23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105286_bib24","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/S2665-9913(23)00064-4","article-title":"Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study","volume":"5","author":"McCarter","year":"2023","journal-title":"Lancet Rheuma"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105286_bib25","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.3390\/cancers14122937","article-title":"Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma","volume":"14","author":"Melin","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105286_bib26","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105286_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103247","article-title":"The immunopathogenesis of sarcoidosis","volume":"149","author":"Miedema","year":"2024","journal-title":"J. Autoimmun."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105286_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf017","article-title":"Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors","volume":"30","author":"Nykaza","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105286_bib29","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105286_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1301991","article-title":"FOXP3+ regulatory T cells are associated with the severity and prognosis of sarcoidosis","volume":"14","author":"Patterson","year":"2023","journal-title":"Front Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105286_bib31","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s10147-019-01490-2","article-title":"Immune checkpoint inhibitor-induced sarcoidosis-like granulomas","volume":"24","author":"Rambhia","year":"2019","journal-title":"Int J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105286_bib32","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.40397","article-title":"Cancer immunotherapy in patients with preexisting rheumatic disease: The Mayo Clinic experience","volume":"70","author":"Richter","year":"2018","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.critrevonc.2026.105286_bib33","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105286_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107640","article-title":"Sarcoid-like reactions to immune checkpoint inhibitors: Incidence, treatment course, and impact on cancer progression and survival","volume":"227","author":"Smith","year":"2024","journal-title":"Respir. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105286_bib35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.36401\/JIPO-22-30","article-title":"Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature","volume":"6","author":"Soto","year":"2023","journal-title":"J. Immunother. Precis Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105286_bib36","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5937\/jomb0-50994","article-title":"ACE and chitotriosidase as possible predictive biomarkers for activity of sarcoidosis in correlation with PET\/CT findings","volume":"44","author":"Stjepanovic","year":"2025","journal-title":"J. Med Biochem"},{"key":"10.1016\/j.critrevonc.2026.105286_bib37","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/438070","article-title":"Bronchoalveolar lavage fluid IFN-\u03b3+ Th17 cells and regulatory T cells in pulmonary sarcoidosis","volume":"2014","author":"T\u00f8ndell","year":"2014","journal-title":"Mediat. Inflamm."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105286_bib38","doi-asserted-by":"crossref","first-page":"T80","DOI":"10.1016\/j.ad.2023.03.011","article-title":"Translated article] Sarcoid-like Reactions to Immune Checkpoint Inhibitors","volume":"115","author":"Torrecilla-Vall-Llossera","year":"2024","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.critrevonc.2026.105286_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1150128","article-title":"Sarcoidosis-like reaction induced by immune checkpoint inhibitor in a patient with hepatocellular carcinoma: a case report","volume":"14","author":"Torres-Zurita","year":"2023","journal-title":"Front Immunol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105286_bib40","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheuma"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105286_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175264","article-title":"Immune mechanisms of granuloma formation in sarcoidosis and tuberculosis","volume":"134","author":"Weeratunga","year":"2024","journal-title":"J. Clin. Invest"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105286_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s43556-025-00244-z","article-title":"Sarcoidosis: molecular mechanisms and therapeutic strategies","volume":"6","author":"Xu","year":"2025","journal-title":"Mol. Biomed."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105286_bib43","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3899\/jrheum.2025-0482","volume":"52","author":"Ye","year":"2025","journal-title":"J. Rheuma"},{"key":"10.1016\/j.critrevonc.2026.105286_bib44","article-title":"The Role of Diverse Immune Cells in Sarcoidosis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2026.105286_bib45","article-title":"Imbalanced distribution of regulatory T cells and Th17.1 cells in the peripheral blood and BALF of sarcoidosis patients: relationship to disease activity and the fibrotic radiographic phenotype","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105286_bib46","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/cac2.12283","article-title":"The five major autoimmune diseases increase the risk of cancer: epidemiological data from a large-scale cohort study in China","volume":"42","author":"Zhou","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.critrevonc.2026.105286_fur1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1731991","article-title":"Serum paraoxonase-1 as a marker of oxidative stress and pulmonary dysfunction in sarcoidosis: association with disease activity and prognostic potential","volume":"16","author":"Bozk\u00fcrk","year":"2026","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105286_fur2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105286_fur3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00262-018-2134-z","article-title":"German Dermatologic Cooperative Oncology Group (DeCOG). Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders","volume":"67","author":"K\u00e4hler","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105286_fur4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.semcancer.2019.06.012","article-title":"Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review","volume":"64","author":"Khan","year":"2020","journal-title":"Semin Cancer Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105286_fur5","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3390\/ijms19030730","article-title":"The Balance of Th17 versus Treg Cells in Autoimmunity","volume":"19","author":"Lee","year":"2018","journal-title":"Int J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105286_fur6","article-title":"Safe Use of Immune Checkpoint Inhibitors in Patients With Autoimmune Disease in a Community Hospital Setting: A Report of Two Cases","volume":"17","author":"Shah","year":"2025","journal-title":"Cureus"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:36:19Z","timestamp":1778481379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":52,"alternative-id":["S1040842826001733"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105286","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When immunity backfires: Meta-analysis on sarcoidosis reactivation in cancer patients treated with immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105286","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105286"}}